

Q4-2022 Pharma Services Update

Market Update

Despite an uncertain macroeconomic environment, recessionary fears, the war in Ukraine, and the impact of rising interest rates, M&A activity in pharma services displayed strong resiliency Q4-22, mostly led by add-on acquisitions to existing platforms. Investors remain attracted to the long-term tailwinds driving growth across outsourced pharma services including reducing costs, technological advancements, access to value-added specialty services. Certain therapeutic areas, oncology and CNS diseases for example, will likely remain popular due to a robust pipeline of R&D activity.

Sellers seeking M&A opportunities to either exit their ownership positions or find a strategic partner to drive growth are positioned to benefit from this continued investor interest and a growing community of well-financed, growth-oriented buyers.

Select Transactions

Month	Acquirer	Target	Commentary
October			Cognitive Research Corporation is a privately-held, full-service contract research organization that specializes in Central Nervous System (CNS) product development for pharmaceutical, nutraceutical, biotechnology and medical device companies.
October			Helios Clinical Research is an integrated clinical site organization that partners with patients, physicians and biopharma sponsors to optimize clinical research.
November			Celerion is a leading global clinical research organization focused on providing end-to-end early stage clinical trial and bioanalytical services to a diverse group of customers. The Company's offering includes clinical trial design, patient recruitment, clinical site management, bioanalytical testing, and data management. Celerion has locations in the United States, Canada, Austria, South Korea, Switzerland, and the United Kingdom.
December			Meridian is a multi-specialty site organization for Phase I-IV clinical trials. As a result of this acquisition, Velocity will have sites in 25 U.S. states, employing over 1500 clinical research professionals.

Notable Transaction



October 2022

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers.

The CDMO will focus on expanding its drug and consumer product capabilities. The Company was acquired for \$408 million.

Provident Industry Coverage Team

Michael Patton
Managing Director
mpatton@providenthp.com
(617) 226-4272

Kevin McDermott
Senior Associate
kmcdermott@providenthp.com
(310) 359-6627

Daniel O'Brien
Associate
dobrien@providenthp.com
(617) 226-4292